Mandrake Bio has raised Rs 16 crore to develop an AI-powered gene-editing platform aimed at advancing agriculture and medicine. The funding round was announced recently, marking a key step in the startup's efforts to integrate artificial intelligence with gene-editing technologies to improve crop yields and medical treatments, according to economictimes.indiatimes.com.
The capital infusion will be used to build and scale Mandrake Bio's platform, which leverages AI algorithms to enhance precision in gene editing. The company aims to accelerate research and development cycles by automating complex genetic modifications. This strategic funding round involved investors focused on biotech and AI innovations, underscoring confidence in Mandrake Bio’s approach to combining these technologies.
This development comes amid growing interest in AI applications within biotechnology, where precision and speed are critical. Comparable startups have attracted significant investments as the global market for gene editing expands, driven by demands in agriculture for resilient crops and in medicine for targeted therapies. Mandrake Bio’s platform could position it competitively in this evolving sector by addressing both agricultural and medical needs with AI-enhanced gene editing.
Mandrake Bio’s Rs 16 crore funding round was disclosed in a recent report by The Economic Times, highlighting the startup’s commitment to advancing AI-driven gene editing. The company is now focused on deploying the capital to accelerate its platform development and expand its research capabilities.